Transfusion Medicine Reviews
Volume 22, Issue 4 , Pages 280-290 , October 2008

Granulocyte Colony–Stimulating Factor Administration: Adverse Events

References 

  1. Dale DC. The discovery, development and clinical applications of granulocyte colony-stimulating factor. Trans Am Clin Climatol Assoc. 1998;109:27–36
  2. Lieschke G, Burgess A. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med. 1992;327:28–35
  3. Frankfurt O, Tallman M. Growth factors in leukemia. J Natl Comp Canc Netw. 2007;5:203–215
  4. Frampton JE, Lee CR, Faulds D. Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs. 1994;48:731–760
  5. Lee S, Chu K, Jung K, et al. Granulocyte colony-stimulating factor enhances angiogenesis after focal cerebral ischemia. Brain Res. 2005;1058:120–128
  6. Kang H, Kim H, Zhang S, et al. Effects of intracoronary infusion of peripheral blood stem cells mobilized with G-CSF on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: The MAGIC cell randomized clinical trial. Lancet. 2004;363:751–756
  7. Morstyn G, Campbell L, Souza LM, et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet. 1988;1:667–672
  8. Anderlini P, Korbling M, Dale D, et al. Allogeneic blood stem cell transplantation: Considerations for donors. Blood. 1997;90:903–908
  9. Stroncek D, Clay M, Petzoldt M, et al. Treatment of normal individuals with granulocyte-colony–stimulating factor: donor experiences and the effects on the peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion. 1996;36:601–610
  10. Anderlini P, Przepiorka D, Seong D, et al. Clinical toxicity and laboratory effects of granulocyte-colony–stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion. 1996;36:590–595
  11. Martinez C, Urbano-Ispizua A, Marin P, et al. Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors. Bone Marrow Transplant. 1999;24:1273–1278
  12. McCullough J, Clay M, Herr G, et al. Effect of granulocyte colony-stimulating factor on potential normal granulocyte donors. Transfusion. 1999;39:1136–1140
  13. LeBlanc R, Roy J, Demers C, et al. A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. Bone Marrow Transplant. 1999;23:991–996
  14. Murata M, Harada M, Kato S, et al. Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors. Bone Marrow Transplant. 1999;24:1065–1071
  15. Bux J, Cassens U, Dielschneider T, et al. Tolerance of granulocyte donors towards granulocyte colony-stimulating factor stimulation and of patients towards granulocyte transfusions: Results of a multicenter study. Vox Sang. 2003;85:322–325
  16. Yoshida I, Matsuo K, Teshima T, et al. Transient respiratory disturbance by granulocyte-colony–stimulating factor administration in healthy donors of allogeneic peripheral blood progenitor cell transplantation. Transfusion. 2006;46:186–192
  17. Arimura K, Inoue H, Kukita T, et al. Acute lung injury in a healthy donor during mobilization of peripheral blood stem cells using granulocyte-colony stimulating factor alone. Haematologica. 2005;90:ECR 10
  18. Kitamura S, Kinouchi K, Fukumitsu K, et al. A risk of pulmonary edema associated with G-CSF pretreatment. Masui. 1997;46:946–950
  19. Azevedo A, Tabak D. Life-threatening capillary leak syndrome after G-CSF mobilization and collection of peripheral blood progenitor cells for allogeneic transplantation. Bone Marrow Transplant. 2001;28:311–312
  20. Spitzer T, McAfee S, Poliquin C, et al. Acute gouty arthritis following recombinant human granulocyte colony-stimulating factor therapy in an allogeneic blood stem cell donor. Bone Marrow Transplant. 1998;21:966–967[letter]
  21. Stroncek D, Shawker T, Follmann D, et al. G-CSF–induced spleen size changes in peripheral blood progenitor cell donors. Transfusion. 2003;43:609–613
  22. Becker P, Wagle M, Matous S, et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): Occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant. 1997;3:45–49
  23. Falzetti F, Aversa F, Minelli O, et al. Spontaneous rupture of spleen during peripheral blood stem-cell mobilization in a healthy donor. Lancet. 1999;353:555;[letter]
  24. Balaguer H, Galmes A, Ventayol G, et al. Splenic rupture after granulocyte-colony–stimulating factor mobilization in a peripheral blood progenitor cell donor. Transfusion. 2004;44:1260–1261
  25. Adler B, Salzman D, Carabasi M, et al. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood. 2001;97:3313–3314[letter]
  26. Azevedo W, Aranha F, Gouvea J, et al. Allogeneic transplantation with blood stem cells mobilized by rhG-CSF for hematological malignancies. Bone Marrow Transplant. 1995;16:647–653
  27. Okamoto S, Ishida A, Wakui M, et al. Prolonged thrombocytopenia after administration of granulocyte colony-stimulating factor and leukapheresis in a donor for allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 1996;18:482–483
  28. Oiso N, Watanabe N, Kawada A. Granulocyte-colony stimulating factor–induced Sweet syndrome in a healthy donor. Br J Haematol. 2006;135:148
  29. Mori T, Sato N, Watanabe R, et al. Erythema exudativum multiforme induced by granulocyte colony-stimulating factor in an allogeneic peripheral blood stem cell donor. Bone Marrow Transplant. 2000;26:239–240
  30. Adkins D. Anaphylactoid reaction in a normal donor given granulocyte colony-stimulating factor. J Clin Oncol. 1998;16:812–813
  31. Parkkali T, Volin L, Siren M, et al. Acute iritis induced by granulocyte colony-stimulating factor used for mobilization in a volunteer unrelated peripheral blood progenitor cell donor. Bone Marrow Transplant. 1996;17:433–434
  32. Kroschinsky F, Hundertmark A, Mauersberger S, et al. Severe autoimmune hyperthyroidism after donation of growth factor–primed allogeneic peripheral blood progenitor cells. Haematologica. 2004;89:ECR 05
  33. Vij R, Adkins D, Brown R, et al. Unstable angina in a peripheral blood stem cell donor given granulocyte-colony–stimulating factor. Transfusion. 1999;39:542–543[letter]
  34. Shimoda K, Okamura S, Inaba S, et al. Granulocyte colony-stimulating factor and platelet aggregation. Lancet. 1993;341:633
  35. Yakisan E, Schirg E, Zeidler C, et al. High incidence of significant bone loss in patients with severe congenital neutropenia (Kostmann's syndrome). J Pediatr. 1997;131:592–597
  36. Bishop N, Williams D, Compston J, et al. Osteoporosis in severe congenital neutropenia treated with granulocyte colony-stimulating factor. Br J Haematol. 1995;89:927–928
  37. Hirbe A, Uluckan O, Morgan E, et al. Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner. Blood. 2007;109:3425–3431
  38. van Os R, Robinson S, Sheridan T, et al. Granulocyte colony-stimulating factor enhances bone marrow stem cell damage caused by repeated administration of cytotoxic agents. Blood. 1998;92:1950–1956
  39. Katayama Y, Deguchi S, Shinagawa K, et al. Bone marrow necrosis in a patient with acute myeloblastic leukemia during administration of G-CSF and rapid hematologic recovery after allotransplantation of peripheral blood stem cells. Am J Hematol. 1998;57:238–240
  40. Punt C, Kingma J. Severe asthenia and fatigue caused by recombinant human granulocyte colony stimulating factor. Ann Oncol. 1994;5:473–474[letter]
  41. Hofmann M, Mahlke M, Casper F, et al. Persistent granulocytosis and hyperuricemia after a single G-CSF injection (filgrastim) in treatment of chemotherapy-induced myelosuppression in metastatic breast carcinoma. Zentralbl Gynakol. 1995;117:314–316
  42. Vidarsson B, Geirsson A, Onundarsson P. Reactivation of rheumatoid arthritis and development of leukocytoclastic vasculitis in a patient receiving granulocyte colony-stimulating factor for Felty's syndrome. Am J Med. 1995;589–591
  43. Hayat S, Hearth-Holmes M, Wolf R. Flare of arthritis with successful treatment of Felty's syndrome with granulocyte colony stimulating factor (GCSF). Clin Rheumatol. 1995;14:211–212
  44. Farhey Y, Herman J. Vasculitis complicating granulocyte colony stimulating factor treatment of leukopenia and infection in Felty's syndrome. J Rheumatol. 1995;22:1179–1182
  45. Iking-Konert C, Ostendorf B, Foede M, et al. Granulocyte colony-stimulating factor induces disease flare in patients with antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol. 2004;31:1655–1658
  46. Sandor V, Hassan R, Kohn E. Exacerbation of pseudogout by granulocyte colony-stimulating factor. Ann Intern Med. 1996;121:781;[letter]
  47. de Luis D, Romero E. Reversible thyroid dysfunction during treatment with G-CSF. Lancet. 1992;340:1169–1170[letter]
  48. Van Hoef M, Howell A. Risk of thyroid dysfunction during treatment with G-CSF. Lancet. 1992;340:1169–1170
  49. Duarte F, de Luis A, Lopez-Jimenez J, et al. Thyroid function and autoimmunity during treatment with G-CSF. Clin Endocrinol (Oxf). 1999;51:133–135[letter]
  50. Hirokawa M, Lee M, Motegi M, et al. Reversible renal impairment during leukocytosis induced by G-CSF in non-Hodgkin's lymphoma. Am J Hematol. 1996;51:328–329[letter]
  51. Magen D, Mandel H, Berant M, et al. MPGN type I induced by granulocyte colony stimulating factor. Pediatr Nephrol. 2002;17:370–372
  52. White J, Mufti G, Salisbury J, et al. Cutaneous manifestations of granulocyte colony-stimulating factor. Clin Exp Dermatol. 2005;31:206–207
  53. Couderc L, Philipe B, Franck N, et al. Necrotizing vasculitis and exacerbation of psoriasis after granulocyte colony-stimulating factor administration for small cell lung carcinoma. Respir Med. 1995;89:237–238[letter]
  54. George S, George B, Gorak E. Erythema nodosum secondary to granulocyte colony-stimulating factor in a patient with Hodgkin lymphoma during CD34+ cell mobilization for autologous peripheral blood stem cell transplantation: A dose mediated effect. Biol Blood Marrow Transplant. 2005;11:816–817[letter]
  55. Nomiyama J, Shinohara K, Inoue H. Erythema nodosum caused by administration of granulocyte colony-stimulating factor in a patient with refractory anemia. Am J Hematol. 1994;47:333;[letter]
  56. Prendiville J, Thiessen P, Mallory S. Neutrophilic dermatoses in two children with idiopathic neutropenia: Association with granulocyte colony-stimulating factor (GCSF) therapy. Pediatr Dermatol. 2001;18:417–421
  57. Dereure O, Bessis D, Levabre-Bertrand T, et al. Thrombotic and necrotizing panniculitis associated with recombinant granulocyte colony-stimulating factor treatment. Br J Dermatol. 2000;142:834–836
  58. Lewerin C, Mobacken H, Nilsson-Ehle H, et al. Bullous pyoderma gangrenosum in a patient with myelodysplastic syndrome during granulocyte colony-stimulating factor treatment. Leuk Lymphoma. 1997;26:629–632
  59. Alvarez-Ruiz S, Penas P, Fernandez-Hererra J, et al. Maculopapular eruption with enlarged macrophages in eight patients receiving G-CSF or GM-CSF. J Eur Acad Dermatol Venereol. 2004;18:310–313
  60. Glass L, Fotopoulos T, Messina J. A generalized cutaneous reaction induced by granulocyte colony-stimulating factor. J Am Acad Dermatol. 1996;34:455–459
  61. Ferran M, Gallardo F, Salar A, et al. Granulomatous dermatitis with enlarged histiocytes: A characteristic pattern of granulocyte colony-stimulating factor. Report of two cases and review of the literature. Dermatology. 2006;212:188–193
  62. Vila A, Puig L, Fernandez-Figueiras A, et al. Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: Clinicopathologic study of five patients. Br J Dermatol. 2005;153:417
  63. Hierholzer C, Kelly E, Lyons V, et al. G-CSF instillation into rat lungs mediates neutrophil recruitment, pulmonary edema and hypoxia. J Leukoc Biol. 1998;63:169–174
  64. Inano H, Kameyama S, Yasui S, et al. Granulocyte colony-stimulating factor induces neutrophil sequestration in rabbit lungs. Am J Respir Cell Mol Biol. 1998;19:167–174
  65. Azoulay E, Attalah H, Harf A, et al. Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: Myth or reality? Systematic review of case reports and experimental data. Chest. 2001;120:1695–1701
  66. Ruiz-Arguelles G, Arizpe-Bravo D, Sanchez-Sosa S, et al. Fatal G-CSF–induced pulmonary toxicity. Am J Hematol. 1999;60:82–83[letter]
  67. Gertz M, Lacy M, Bjornsson J, et al. Fatal pulmonary toxicity related to the administration of granulocyte colony-stimulating factor in amyloidosis: A review and report of growth factor–induced pulmonary toxicity. J Hematother Stem Cell Res. 2000;9:635–643
  68. van Woensal J, Knoester H, Leum J, et al. Acute respiratory insufficiency during doxorubicin, cyclophosphamide and G-CSF therapy. Lancet. 1994;344:759–760[letter]
  69. Azoulay E, Herigault S, Levame M, et al. Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis. Crit Care Med. 2003;31:1442–1448
  70. Couderc L, Stelianides S, Frachon I, et al. Pulmonary toxicity of chemotherapy and G/GM-CSF: A report of five cases. Respir Med. 1999;93:65–68
  71. Yokose N, Ogata K, Tamura H, et al. Pulmonary toxicity after granulocyte colony-stimulating factor–combined chemotherapy for non-Hodgkin's lymphoma. Br J Cancer. 1998;77:2286–2290
  72. Niitsu N, Iki S, Muroi K, et al. Interstitial pneumonia in patients receiving granulocyte colony-stimulating factor during chemotherapy: Survey in Japan. 1991-96 Br J Cancer. 1997;76:1661–1666
  73. Hill J, Syed M, Arai A, et al. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol. 2005;46:1643–1648
  74. Fukumoto Y, Miyamoto M, Okamura T, et al. Angina pectoris occurring during granulocyte colony-stimulating factor–combined preparatory regimen for autologous peripheral stem cell transplantation in a patient with acute myelogenous leukemia. Br J Haematol. 1997;97:666–668
  75. Sinha S, Poh K, Sodano D, et al. Safety and efficacy of peripheral blood progenitor cell mobilization and collection in patients with advanced coronary artery disease. J Clin Apher. 2006;21:116–120
  76. Conti J, Scher H. Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy with granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicity. Cancer. 1992;70:2699–2702
  77. Kawachi Y, Watanabe A, Uchida T, et al. Acute arterial thrombosis in a patient due to platelet aggregation receiving granulocyte colony-stimulating factor. Br J Haematol. 1996;94:413–416
  78. Kato Y, Kuwabara T, Itoh T, et al. A possible relationship between abortions and placental embolism in pregnant rabbits given granulocyte colony-stimulating factor. J Toxicol Sci. 2001;26:39–50
  79. Huttmann A, Duhrsen U, Stypmann J, et al. Granulocyte colony-stimulating factor–induced blood stem cell mobilization in patients with chronic heart failure—feasibility, safety and effects on exercise tolerance and cardiac function. Basic Res Cardiol. 2006;101:78–86
  80. Wang Y, Tagil K, Ripa R, et al. Effect of mobilization of bone marrow stem cells by granulocyte colony stimulating factor on clinical symptoms, left ventricular perfusion and function in patients with severe chronic ischemic heart disease. Int J Cardiol. 2005;100:477–483
  81. Haghighat A, Weiss D, Whalin M, et al. Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor exacerbate atherosclerosis in apolipoprotein E–deficient mice. Circulation. 2007;115:2049–2054
  82. Darie C, Boutalba S, Fichter P, et al. Aortitis after G-CSF injections. Rev Med Interne. 2004;25:225–229
  83. Dareen D, Zachee P, Manu L, et al. Granulocyte colony-stimulating factor-induced capillary leak syndrome confirmed by extravascular lung water measurements. Ann Hematol. 2005;84:89–94
  84. Oeda I, Shinohara K, Kamei S, et al. Capillary leak syndrome likely the result of granulocyte colony-stimulating factor after high-dose chemotherapy. Intern Med. 1994;33:115–119
  85. Jaiyesimi I, Giralt S, Wood J. Subcutaneous granulocyte-colony stimulating factor and acute anaphylaxis. N Engl J Med. 1991;325:587;[letter]
  86. Kanbayashi Y, Mukoyama N, Nishida K, et al. Two cases of malignant lymphoma with high fever and C-reactive protein (CRP) elevation after treatment with granulocyte colony-stimulating factor (G-CSF). Kan To Kagaku Ryoho. 2006;33:73–77
  87. Mueller B, Burt R, Gulick L, et al. Disseminated intravascular coagulation associated with granulocyte colony-stimulating factor therapy in a child with human immunodeficiency virus infection. J Pediatr. 1995;126:749–752
  88. Abboud M, Laver J, Blau C. Granulocytosis causing sickle-cell crisis. Lancet. 1998;351:959;[letter]
  89. Wei A, Grigg A. Granulocyte colony-stimulating factor–induced sickle cell crisis and multiorgan dysfunction in a patient with a compound heterozygous sickle cell/β+ thalessemia. Blood. 2001;97:3998–3999[letter]
  90. O'Malley D, Whalen M, Banks P. Spontaneous splenic rupture with fatal outcome following G-CSF administration for myelodysplastic syndrome. Am J Hematol. 2003;73:294–295[letter]
  91. Litam P, Friedman H, Loughran T. Splenic extramedullary hematopoiesis in a patient receiving intermittently administered granulocyte colony-stimulating factor. Ann Intern Med. 1993;118:954–955[letter]
  92. Dagdas S, Ozet G, Alanoglu G, et al. Unusual extramedullary hematopoiesis in a patient receiving granulocyte colony-stimulating factor. Acta Haematol. 2006;116:198–202
  93. Reykdal S, Sham R, Phatak P, et al. Pseudoleukemia following the use of G-CSF. Am J Hematol. 1995;49:258–259
  94. Arici M, Hazendaroglu I, Erman M, et al. Leukoerythroblastosis following the use of G-CSF. Am J Hematol. 1998;52:123–124[letter]
  95. Jeha S, Chan K, Aprikyan A, et al. Spontaneous remission of granulocyte colony-stimulating factor-associated leukemia in a child with severe congenital neutropenia. Blood. 2000;96:3647–3649
  96. Schrijvers D, Slootmaekers V, Dirix L, et al. Neurological disturbances due to filgrastim. Lancet. 1997;349:402–403[letter]
  97. Matsumura T, Maruyama-Tabata H, Kuwahara Y, et al. Subretinal hemorrhage after granulocyte colony-stimulating factor. Lancet. 1996;348:1506;[letter]
  98. Papaldo P, Ferretti G, Di Cosimo S, et al. Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?. J Clin Oncol. 2006;24:3048–3055
  99. Volpi I, Perruccio K, Tosti A, et al. Postgrafting administration of granulocyte colony-stimulating factor impairs functional recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood. 2001;97:2514–2521
  100. Ringden O, Labopin M, Gorin N, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death. J Clin Oncol. 2004;22:416–423
  101. Rosenberg P, Alter B, Bolyard A, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood. 2006;107:4628–4635
  102. Freedman M, Bonilla M, Fier C, et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood. 2000;96:429–436
  103. Sloand E, Yong A, Ramkissoon S, et al. Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci U S A. 2006;103:14483–14488
  104. Socie G, Mary J, Schrezenmeier H, et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Bone Marrow Transplantation (EBMT). Blood. 2007;109:2794–2796
  105. Kaito K, Kobayashi M, Katayama T, et al. Long-term administration of G-CSF for aplastic anemia is closely related to the early evolution of monosomy 7 MDS in adults. Br J Haematol. 1998;103:297–303
  106. Hershman D, Neugut A, Jacobson J, et al. Acute myeloid leukemia or myelodysplastic syndrome following the use of granulocyte colony-stimulating factor during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007;99:196–205
  107. Di Cosimo S, Ferretti G, Papaldo P, et al. Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukemia in breast cancer women?. Ann Oncol. 2005;16:1209–1210[letter]
  108. de la Rubia J, Bonanad S, Palau J, et al. Rapid progression of multiple myeloma following G-CSF mobilization. Bone Marrow Transplant. 1994;14:475–476
  109. Fata F, Myers P, Addeo J, et al. Acceleration of leukaemia with granulocyte colony-stimulating factor in a patient with aleukemic leukemia. Br J Hosp Med. 1997;58:111–112
  110. Kawachi Y, Ozaki S, Sakamoto Y, et al. Richter's syndrome showing pronounced lymphadenopathy at the site of G-CSF injection in acute myelocytic leukemia. Leuk Lymphoma. 1994;13:509–514
  111. Duhrsen U, Renges H, Mayer U, et al. Leukemic nodules at the site of G-CSF injection in acute myelomonocytic leukemia. Eur J Haematol. 1995;54:51–52
  112. Kikuchi M, Inagaki T, Ueda R, et al. A case of multiple myeloma with infiltration into skeletal muscle after injections of a granulocyte-colony stimulating-factor. Nippon Ronen Igakkai Zasshi. 2002;39:433–438

PII: S0887-7963(08)00041-2

doi: 10.1016/j.tmrv.2008.05.005

Transfusion Medicine Reviews
Volume 22, Issue 4 , Pages 280-290 , October 2008

Article Tools